NASDAQ · Industrials

Evogene Ltd. (EVGN)

Evogene Ltd. reported revenue of $3.9M in fiscal 2025, down 30.9% from a year earlier. It posted a net loss of $8.5M. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At December 31, 2025 it held $13M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 26, 2026.

Watch EVGN in 60 seconds

Price

$0.42

-1.96% on the day · September 25, 2026

52-week range $0.37 to $1.50

Market cap

$5.5M

Revenue (FY2025)

$3.9M

-30.9% year on year

Net margin

-220.2%

What Evogene Ltd. does

Evogene Ltd. is registered with the SEC under industry code SIC 2870 (Agricultural Chemicals). Its shares trade on NASDAQ under the ticker EVGN.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$3.9M	-$14M	-$8.5M	$1.08	-$13.6M
2024	$5.6M	-$18.8M	-$16.5M	-$2.90	-$20.3M
2023	$3M	-$22.2M	-$23.9M	-$5.20	-$22.2M
2022	$1.7M	-$26.9M	-$26.6M	-$6.44	-$24.8M
2021	$930K	-$31M	-$27.8M	-$6.84	-$25.6M
2020	$1M	-$24.8M	-$23.4M	-$8.22	-$20.2M

Full financial statements: income, balance sheet and cash flow

Where EVGN ranks in Industrials

Revenue$3.9M

#488 of 518 in Industrials · Bottom 6%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Industrials

Latest SEC filings

What Evogene Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 15, 2026
Foreign issuer update 6-K
September 11, 2026
Activist stake changed SCHEDULE 13D/A
September 11, 2026
Activist stake changed SCHEDULE 13D/A
September 4, 2026
Foreign issuer update 6-K
August 28, 2026
Activist stake changed SCHEDULE 13D/A
August 27, 2026
Foreign issuer update 6-K
August 18, 2026
Foreign issuer update 6-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Activist stake changed SCHEDULE 13D/A
August 13, 2026
Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 26, 2026. Insider transactions on SEC

Insider trades

What the people running Evogene Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $692.1K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$692.1K

last 90 days

Sold

last 90 days

Net bought

1,260,000

$692.1K

Date	Insider	What	Shares	Price	Value	Filing
August 11, 2026	Recanati LeonDirector	Bought	460,000	$0.64	$292.1K	Form 4
August 4, 2026	Recanati LeonDirector	Bought	800,000	$0.50	$400K	Form 4
June 4, 2026	Tarcic GabiChief Development Officer	Bought	1,129	$0.60	$677.4	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns EVGN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
L.I.A. Pure Capital Ltd.13D, may seek influence with 3 related filers	19.35%	3,057,488	September 11, 2026
Recanati Leon13D, may seek influence	8.6%	1,354,836	September 11, 2026

Latest filings below 5%: Armistice Capital, LLC 4.99% (August 14, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 1,345,015 shares in total, about $559.5K at the last price.

Holder	Shares	As of
Recanati LeonDirector	1,343,886	August 11, 2026
Tarcic GabiChief Development Officer	1,129	June 4, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about EVGN

What does Evogene Ltd. do?

Evogene Ltd. is registered with the SEC under industry code SIC 2870 (Agricultural Chemicals). Its shares trade on NASDAQ under the ticker EVGN.

Is Evogene Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $8.5M on revenue of $3.9M.

How much revenue does Evogene Ltd. make?

In fiscal 2025 Evogene Ltd. reported revenue of $3.9M. That is 30.9% less than a year earlier.

When did Evogene Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 26, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 15, 2026.

Similar companies

CF Industries Holdings, Inc.

SMG

Scotts Miracle-Gro Co

UAN

Cvr Partners, LP

Compare EVGN with

Compare EVGN with any company

Follow EVGN

Get an email when Evogene Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow EVGN: get an email when it files

Where the numbers come from

Financial figures are the values Evogene Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.